Welcome to our dedicated page for Virax Biolabs Group news (Ticker: VRAX), a resource for investors and traders seeking the latest updates and insights on Virax Biolabs Group stock.
Virax Biolabs Group Limited (NASDAQ: VRAX) is a biotechnology company focused on the detection of immune responses and diagnosis of viral diseases, with a particular emphasis on T cell-based diagnostics and post-acute infection syndromes (PAIS) such as Long COVID. The VRAX news feed on Stock Titan aggregates company-issued updates and market-moving announcements so readers can follow how Virax’s clinical, regulatory, and financing activities evolve over time.
News about Virax frequently covers progress with its ViraxImmune™ T cell assay and related immune-profiling work. This includes clinical milestones in the United Kingdom, where the company has initiated and completed recruitment for a multi-centre PAIS study conducted with the NHS, and collaborations in the United States, such as its Research Services Agreement with Emory University to generate clinical data in post-viral syndromes including Long COVID. Regulatory interactions, for example Virax’s pre-submission meeting with the U.S. Food and Drug Administration (FDA) and its plans for submissions to the UK Medicines and Healthcare products Regulatory Agency (MHRA), are also key themes in its announcements.
Investors and observers will also find updates on capital markets transactions, such as private placements of ordinary shares and preferred investment options, and corporate governance developments, including board changes and the appointment of directors with diagnostics and MedTech experience. In addition, Virax issues releases on scientific presentations, such as data on T cell dysfunction in PAIS presented at the World Immune Regulation Meeting in Davos.
By following VRAX news, readers can track how Virax advances its immune-profiling platform, responds to Nasdaq listing requirements, and pursues its stated goal of developing T cell-based diagnostics for chronic and post-viral conditions. Bookmark this page to monitor new clinical data, regulatory updates, financing announcements, and scientific disclosures related to Virax Biolabs.
Virax Biolabs Group Limited (Nasdaq: VRAX) has received Emergency Use Authorization (EUA) from the U.S. FDA for its Over-the-Counter COVID-19 Rapid Antigen Test. This milestone enables Virax to distribute the test in the U.S., with manufacturing capacity up to 2 million tests per day. The test aims to identify COVID-19 infections, boasting 98.8% sensitivity and 97.2% specificity. Additionally, Virax seeks approval for another antigen test in Canada. This comes amidst significant COVID-19 statistics, including 45 million cases and extensive testing in 2022, highlighting the ongoing demand for effective testing solutions.
Virax Biolabs (Nasdaq: VRAX) has appointed Richard Pallin as Vice President of In Vitro Diagnostic Sales. With nearly 25 years of experience in commercialization of novel technologies, Pallin aims to enhance the company's commercial capabilities and lead its sales strategy. Previously, he held senior roles at notable companies like Omixon and Genmark Diagnostics. This appointment is expected to strengthen Virax's position in the viral diagnostics market, particularly as the company develops a proprietary T-Cell Test technology targeting significant viral threats.
Virax Biolabs Group Limited (Nasdaq: VRAX) has successfully closed a private placement of 2,330,000 ordinary shares at $1.65 per share, raising approximately $3.8 million. In conjunction with this, the company issued warrants for 3,495,000 shares, with an exercise price of $1.73, exercisable in six months and expiring in five and a half years. Proceeds will support the development of the proprietary T-Cell Test technology, alongside general corporate purposes. Roth Capital Partners, LLC acted as the exclusive placement agent for this transaction.
Virax Biolabs Group Limited (Nasdaq: VRAX) announced a private placement to sell 2,330,000 shares at $1.65 per share, raising approximately $3.8 million before fees. In addition to the share sale, the company will issue warrants to purchase up to 3,495,000 shares at an exercise price of $1.73.
The net proceeds will fund the development of Virax's proprietary T-Cell Test technology and support working capital needs. The transaction is anticipated to close around November 8, 2022.
Virax Biolabs (Nasdaq: VRAX) announced the launch of its RSV-Influenza-COVID Triple Virus Antigen Rapid Test Kit for distribution in CE-mark markets, including the EU, in November 2022. This kit enables rapid detection of RSV, influenza, and COVID-19 within 15 minutes, enhancing at-home and point-of-care testing capabilities. RSV is notably a significant cause of hospitalization among infants and the elderly. The company's CEO, James Foster, emphasized its importance amidst rising infection rates in major economies.
Virax Biolabs Group Limited (Nasdaq: VRAX) announced the initiation of its Virax Immune COVID-19 Analytical Performance Study, scheduled for Q4 2022 to Q1 2023. The study aims to evaluate the technical performance of its Virax Immune COVID-19 Flow Cytometry Kit using specimens from 96 healthy volunteers. This proprietary T-Cell In-Vitro Diagnostic test technology seeks to assess individual immune risk profiles against viral threats, including COVID-19. The company plans to develop tests for other viruses, promoting affordability and scalability in diagnostics.
Virax Biolabs Group Limited (Nasdaq: VRAX) has entered an exclusive distribution agreement with Cosmos Holdings Inc. (Nasdaq: COSM) to market Monkeypox Virus Real-Time PCR Detection Kits in Greece and Cyprus, with non-exclusive distribution rights across Europe. This partnership aims to enhance rapid diagnosis and containment of the Monkeypox virus, a growing global health concern with over 61,000 confirmed cases reported in 104 countries as of September 16, 2022. Financial terms of the deal remain undisclosed.
Virax Biolabs (NASDAQ: VRAX) announced that CEO James Foster presented at H.C. Wainwright's 24th Annual Global Investment Conference in New York from September 12-14, 2022. The presentation is available on-demand. Virax is focused on innovative biotechnology solutions, particularly immunology profiling against viral diseases. The company is developing T-Cell Test technology for diagnosing and assessing immune risks related to COVID-19 and other viral threats like Monkeypox and Hepatitis B.
Virax Biolabs Group Limited (Nasdaq: VRAX), a biotech company focused on viral disease detection, announced that its CEO, James Foster, will present at H.C. Wainwright's 24th Annual Global Investment Conference from September 12-14, 2022, in New York, NY. The presentation will be available on-demand starting September 12 at 7:00 AM EST. Virax specializes in T-Cell Test technology for assessing immune risk profiles against major viral threats, including COVID-19 and Monkeypox. The company aims to enhance immunity profiling in viral disease management.
Summary not available.